Last reviewed · How we verify
NCT07587294
Efficacy and Safety of Ultrasound Modulation of Stellate Ganglion for the Prevention of Ventricular Arrhythmia in Patients With ST-segment Elevation Myocardial Infarction
NA trial testing Ultrasound modulation of the left stellate ganglion in Acute ST-segment Elevation Myocardial Infarction (Patients Undergoing Emergency PCI) in 100 participants. Not yet recruiting.
Quick facts
| Lead sponsor | Renmin Hospital of Wuhan University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Enrollment | 100 |
| Start date | 5 May 2026 |
| Estimated completion | 1 April 2027 |
Drugs / interventions tested
- Ultrasound modulation of the left stellate ganglion
- Sham ultrasound modulation of the left stellate ganglion
Conditions studied
- Acute ST-segment Elevation Myocardial Infarction (Patients Undergoing Emergency PCI) — all drugs for Acute ST-segment Elevation Myocardial Infarction (Patients Undergoing Emergency PCI) →
Sponsor
Renmin Hospital of Wuhan University
Who can join
Eligibility, any sex, with Acute ST-segment Elevation Myocardial Infarction (Patients Undergoing Emergency PCI).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07587294
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Renmin Hospital of Wuhan University trials
Trials by the same sponsor.
- NCT07269509 — Evaluation of the Efficacy and Safety of an Intensified Strategy of Intratonsillar Immunotherapy (ITIT) for Allergic Rhi · NA · not yet recruiting
- NCT07151560 — Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in · Phase 2 · not yet recruiting
- NCT07085221 — Digital Out-of-hospital Management on Clinical Outcomes in Patients With Early Cardiogenic Shock · NA · recruiting
- NCT06614985 — The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy · Phase 2 · not yet recruiting
- NCT06656962 — The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN · Phase 1, PHASE2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07587294 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Renmin Hospital of Wuhan University
- Last refreshed: recently
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07587294.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing